Sinovac Beijing Completed Its 23-Valent Pneumococcal Polysaccharide Vaccine Phase III Clinical Trial And Filed The New Drug Application To CFDA

Published: Oct 12, 2017

NEW YORK, Oct. 12, 2017 /PRNewswire/ -- According to the latest announcement from CFDA, and Sinovac Beijing, the principal operation subsidiary of Sinovac Biotech (Nasdaq: SVA, "Sinovac"), has accomplished its 23-valent Pneumococcal Polysaccharide Vaccine Phase III clinical trial and filed the New Drug Application to CFDA (reference number: CXSS1700012) on August, 3rd. This vaccine is used to prevent streptococcus pneumoniae (pneumococcus) infections, such as pneumonia and septicemia among adults aged 65 or older, adults with serious long-term health problems, smokers, and children older than two years with serious long-term health problems.

Only Merck Sharp&Dohme, Sanofi Pasteur, Chengdu Institute of Biological Products and Walvax Biotechnology have launched the 23-valent PPV so far. Sinovac will be the third in the domestic vaccine industry.

Based on the National Institutes for Food and Drug Control lot release records, an average of 6.23 million doses of 23-valent PPV has been approved and released in China over the past five years, and its market in China is expected to be 1.24 billion CNY according to the latest bidding price as 200 CNY per dose. Most of 23-valent PPV are vaccinated in the younger population, while less for the adults aged 65 or older who also have the high risk of pneumococcus infection. With the acceleration of population aging and improvement of people's health awareness, the 23-valent PPV market has huge potential in the future.

The data provided in this news is official data or from Announcement of listed company. It is believed that it will strengthen the resolution of Sinobioway to continue the privatization of SVA at the price of $8 per share.

View original content:

SOURCE Shandong Sinobioway Biomedicine Co.,Ltd

Back to news